Abstract Fat mass is no longer viewed as a passive energy reservoir but as a highly dynamic, metabolically active organ that integrates systemic energy homeostasis, immune function, and thermoregulation. Recent advances in single-cell omics, spatial transcriptomics, and engineered thermogenic models have reshaped our understanding of adipose tissue heterogeneity, plasticity, and crosstalk with other organs. This review highlights breakthrough findings on adipocyte progenitor commitment, beige adipocyte induction, lipolysis regulation, and the emerging role of extracellular vesicles in inter-organ communication. We also discuss novel therapeutic strategies targeting fat mass, including mitochondrial uncouplers, epigenetic modulators, and cell-based therapies, while addressing unresolved questions about depot-specific functions and long-term safety.

1. Introduction For decades, fat mass was quantified simply as body fat percentage or BMI, and its reduction was the primary goal of metabolic interventions. However, the discovery of leptin in 1994 (Zhang et al.,Nature) initiated a paradigm shift, revealing adipose tissue as a bona fide endocrine organ. Since then, fat mass has been implicated in insulin sensitivity, inflammation, and even cognitive function. The past five years have witnessed an explosion of high-resolution technologies that allow us to dissect fat mass at the level of individual cells, revealing unexpected heterogeneity and plasticity. This article synthesizes recent findings and projects future directions in fat mass research.

2. Cellular heterogeneity and progenitor dynamics Single-cell RNA sequencing (scRNA-seq) has revolutionized our view of adipose tissue composition. A landmark study by Emont et al. (2022,Nature Genetics) profiled over 160,000 cells from human visceral and subcutaneous fat, identifying distinct adipocyte subtypes with differential expression of thermogenic and lipogenic genes. Notably, they found a previously unrecognized population of “adipose-associated macrophages” that actively remodel extracellular matrix, influencing fat mass expansion. Concurrently, spatial transcriptomics (e.g., Slide-seq) has revealed zonal organization within fat depots, showing that adipocytes near blood vessels exhibit higher metabolic activity than those in hypoxic cores (Bäckdahl et al., 2021,Cell Reports).

Progenitor cell commitment is another frontier. Using lineage tracing in mice, Merrick et al. (2019,Cell Stem Cell) demonstrated that PDGFRα+ progenitor cells give rise to both white and beige adipocytes, but their fate is determined by local cues such as BMP7 and mechanical stiffness. More recently, single-nucleus ATAC-seq has identified transcription factor networks (e.g., EBF2, ZFP423) that maintain adipocyte identity, offering potential targets for reprogramming white adipocytes into energy-burning beige cellsin vivo.

3. Beige adipogenesis and thermogenic plasticity Beige adipocytes, which emerge within white fat depots upon cold exposure or β3-adrenergic stimulation, represent a promising avenue for increasing energy expenditure. A key breakthrough came from the discovery of “Pdgfrα+ smooth muscle-like” precursors that can differentiate into beige cells (Vishvanath et al., 2016,Cell Metabolism). However, the stability of beige fat remains controversial. Recent work by Roh et al. (2023,Nature Metabolism) showed that beige adipocytes undergo “retro-differentiation” to a white-like state upon warm re-exposure, driven by the histone demethylase KDM4A. This suggests that maintaining beige fat requires continuous stimulation or epigenetic stabilization.

Another exciting development is the identification of “thermogenic adipocytes” in humans with a distinct gene signature (e.g.,UCP1,CKMT2,SLC25A33) that correlates with improved metabolic health, independent of total fat mass (Giroud et al., 2022,Cell Reports Medicine). This challenges the simplistic view that all fat mass is detrimental, proposing instead that “healthy fat” may exist in certain depots.

4. Lipolysis and mitochondrial dynamics Fat mass reduction depends on lipolysis, which is tightly regulated by hormonal signals and intracellular lipid droplet proteins. A recent study by Grabner et al. (2021,Journal of Clinical Investigation) identified a new lipolysis regulator, “LDAF1” (lipid droplet assembly factor 1), which controls the access of lipases to triglycerides. Knockout of LDAF1 in mice resulted in resistance to diet-induced obesity, suggesting a druggable target.

Mitochondrial dynamics within adipocytes have also gained attention. Fragmented mitochondria are associated with reduced oxidative capacity and increased reactive oxygen species, promoting fat accumulation. In contrast, fusion-promoting protein MFN2 overexpression in adipose tissue enhances fatty acid oxidation and protects against obesity (Mann et al., 2022,Nature Communications). These findings open avenues for mitochondrial-targeted therapies.

5. Extracellular vesicles and inter-organ crosstalk Adipose tissue secretes extracellular vesicles (EVs) that carry proteins, lipids, and microRNAs, acting as systemic messengers. A pioneering study by Thomou et al. (2017,Nature) showed that adipose-derived miR-99b regulates hepatic FGF21 expression, linking fat mass to liver metabolism. More recently, Crewe et al. (2023,Cell Metabolism) demonstrated that EVs from obese adipose tissue induce insulin resistance in skeletal muscle by delivering ceramides, while EVs from cold-exposed adipose tissue convey pro-thermogenic signals to the brain. This EV-mediated communication network suggests that fat mass influences distant organs far beyond classical adipokine signaling.

6. Therapeutic innovations and clinical translation The most notable clinical advance is the development of GLP-1 receptor agonists (e.g., semaglutide) that reduce fat mass by ~15% with concurrent improvements in cardiovascular outcomes (Wilding et al., 2021,NEJM). However, these drugs also cause loss of lean mass, prompting research into combination therapies. A recent phase II trial tested the mitochondrial uncoupler BAM15, which increases energy expenditure without affecting food intake (Chouchani et al., 2022,Nature Medicine). Results showed a 7% reduction in fat mass over 12 weeks with preserved muscle mass.

Cell-based therapies are also emerging. Autologous transplantation of beige adipocyte precursors into subcutaneous depots of obese mice resulted in sustained thermogenesis and improved glucose tolerance (Wang et al., 2023,Science Translational Medicine). Meanwhile, epigenetic drugs like HDAC inhibitors are being explored to reactivate brown fat genes in white adipocytes, though off-target effects remain a concern.

7. Future perspectives and unresolved questions Despite these advances, several critical questions remain. First, how do different fat depots (e.g., epicardial, perivascular) contribute to systemic disease? Depot-specific targeting is still in its infancy. Second, the long-term safety of forced beige adipogenesis is unknown—could chronic UCP1 activation lead to mitochondrial dysfunction or carcinogenic stress? Third, the interplay between fat mass and the gut microbiome is underexplored; recent data suggest that microbial metabolites like butyrate can influence adipocyte thermogenesis (Li et al., 2023,Gut). Finally, personalized approaches that consider genetic variants (e.g.,FTO,PPARG) will be essential for tailoring interventions.

Conclusion Fat mass has evolved from a passive marker of obesity to a central hub of metabolic regulation. The integration of single-cell technologies, advanced imaging, and engineered animal models has uncovered unprecedented complexity in adipocyte biology. As we move toward precision medicine, targeting fat mass will require not only reducing its quantity but also modulating its quality—favoring thermogenic, insulin-sensitive, and anti-inflammatory phenotypes. The next decade will likely see the translation of these mechanistic insights into viable therapies for obesity and its comorbidities.

References (selected)